Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm

Trial Profile

Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Digoxin (Primary) ; Ivabradine (Primary)
  • Indications Chronic heart failure; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms DIVA-REF
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top